Neoadjuvant immunotherapy has become a standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC), but predictive biomarkers for treatment efficacy remain limited. This study investigates the role of serum interleukin-6 (IL-6) levels as a prognostic biomarker in patients receiving neoadjuvant immunotherapy for ESCC.
Methods:
A retrospective cohort study was conducted in 47 patients with locally advanced ESCC who underwent neoadjuvant immunochemotherapy followed by esophagectomy. Pretreatment serum levels of IL-6 and the combined positive score were analyzed. Pathological responses were evaluated using the College of American Pathologists Tumor Regression Grade system, and survival outcomes were assessed by Kaplan–Meier analysis. IL-6 knockout mice models were used to validate the impact of IL-6 on anti-PD-1 therapy efficacy.
Results:
Lower pretreatment serum IL-6 levels were significantly associated with better pathological response compared with higher IL-6 levels. Elevated IL-6 levels (>61.495 pg/mL) were identified as an independent risk factor for poorer disease-free survival and overall survival. IL-6 deficiency enhanced the efficacy of anti-PD-1 therapy in mice, reducing tumor burden compared with wild-type controls. Conversely, exogenous IL-6 administration attenuated anti-PD-1 effects. Mechanistically, lower serum IL-6 levels increased CD8+ T cell activation and decreased the regulatory T cell proportion during immunotherapy.
Conclusions:
Low serum IL-6 levels enhance the efficacy of neoadjuvant immunotherapy in locally advanced ESCC.
BrayF, LaversanneM, SungH, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024; 74(3):229–263; doi: 10.3322/caac.21834
2.
HanB, ZhengR, ZengH, et al.Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024; 4(1):47–53; doi: 10.3760/cma.j.cn112152-20240119-00035
3.
DeboeverN, JonesCM, YamashitaK, et al.Advances in diagnosis and management of cancer of the esophagus. BMJ, 2024; 385:e074962; doi: 10.1136/bmj-2023-074962
4.
KatoK, MachidaR, ItoY, et al.; JCOG1109 investigators. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): A randomised, controlled, open-label, phase 3 trial. Lancet, 2024; 404(10447):55–66; doi: 10.1016/S0140-6736(24)00745-1
5.
YanX, DuanH, NiY, et al.Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). Int J Surg, 2022; 103:106680; doi: 10.1016/j.ijsu.2022.106680
6.
LeeY, SamarasingheY, LeeMH, et al.Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and esophagectomy: A systematic review and meta-analysis. Ann Surg, 2022; 275(1):91–98; doi: 10.1097/SLA.0000000000005227
7.
HuangH, ZhaoG, WangT, et al.Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies. Cancer Lett, 2024; 601:217178; doi: 10.1016/j.canlet.2024.217178
8.
ShojiY, KoyanagiK, KanamoriK, et al.Immunotherapy for esophageal cancer: Where are we now and where can we go. World J Gastroenterol, 2024; 30(19):2496–2501; doi: 10.3748/wjg.v30.i19.2496
9.
GeF, HuoZ, CaiX, et al.Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: A systematic review and meta-analysis. JAMA Netw Open, 2022; 5(11):e2239778; doi: 10.1001/jamanetworkopen.2022.39778
10.
ZhangX, CaiX, YanC. Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer. J Cancer Res Clin Oncol, 2023; 149(20):18253–18270; doi: 10.1007/s00432-023-05499-z
11.
ChenX, XuX, WangD, et al.Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): An open-label, single-arm, phase 2 trial. J Immunother Cancer, 2023; 11(2):e005830; doi: 10.1136/jitc-2022-005830
12.
XieQ, LuoY, PengX. Cost-effectiveness analysis of pembrolizumab for patients with advanced esophageal cancer at PD-L1 combined positive score ≥10. J Comp Eff Res, 2022; 11(15):1095–1103; doi: 10.2217/cer-2021-0165
13.
JanjigianYY, ShitaraK, MoehlerM, et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet, 2021; 398(10294):27–40; doi: 10.1016/S0140-6736(21)00797-2
14.
JanjigianYY, AjaniJA, MoehlerM, et al.First-Line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-Year follow-up of the phase III CheckMate 649 trial. J Clin Oncol, 2024; 42(17):2012–2020; doi: 10.1200/JCO.23.01601
15.
RafaqatS, KhurshidH, HafeezR, et al.Role of interleukins in pancreatic cancer: A literature review. J Gastrointest Cancer, 2024; 55(4):1498–1510; doi: 10.1007/s12029-024-01111-w
16.
ŠvajgerU, KamenšekU. Interleukins and interferons in mesenchymal stromal stem cell-based gene therapy of cancer. Cytokine Growth Factor Rev, 2024; 77:76–90; doi: 10.1016/j.cytogfr.2024.03.002
17.
NianZ, DouY, ShenY, et al.Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation. Immunity, 2024; 57(10):2344–2361.e7; doi: 10.1016/j.immuni.2024.08.015
18.
ChangZ, GuoX, LiX, et al.Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization. Cell, 2025; 188(7):1842–1857.e20; doi: 10.1016/j.cell.2025.02.002
19.
RebernickRJ, BellHN, BauerTM, et al.Role of IL4 and GMCSF in predicting survival in esophageal cancer. J Am Coll Surg, 2023; 236(1):107–115; doi: 10.1097/XCS.0000000000000446
20.
KitamuraY, KomaY-I, TanigawaK, et al.Roles of IL-7R induced by interactions between cancer cells and macrophages in the progression of esophageal squamous cell carcinoma. Cancers (Basel), 2023; 15(2):394; doi: 10.3390/cancers15020394
21.
ShebrainS. Predictive survival power of combined Tumor Regression Grade (TRG) and lymph node status in patients with esophageal cancer. J Invest Surg, 2023; 36(1):1–2; doi: 10.1080/08941939.2022.2142869
22.
Freites-MartinezA, SantanaN, Arias-SantiagoS, et al.Using the common terminology criteria for adverse events (CTCAE—Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed), 2021; 112(1):90–92; doi: 10.1016/j.ad.2019.05.009
23.
LiuZ, SuR, AhsanA, et al.Esophageal squamous cancer from 4NQO-Induced mice model: CNV alterations. Int J Mol Sci, 2022; 23(22):14304; doi: 10.3390/ijms232214304
24.
YinJ, YuanJ, LiY, et al.Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: A phase 1b trial. Nat Med, 2023; 29(8):2068–2078; doi: 10.1038/s41591-023-02469-3
25.
YangX, YinH, ZhangS, et al.Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg, 2025; 169(1):289–300.e6; doi: 10.1016/j.jtcvs.2024.06.020
26.
ParkS, LeeY, LeeJ, et al.Neoadjuvant nivolumab therapy for esophageal squamous cell carcinoma: A single-arm, phase II study. Cancer Res Treat, 2024; 56(2):567–579; doi: 10.4143/crt.2023.897
27.
LiuZ, ZhangY, MaN, et al.Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell, 2023; 41(11):1852–1870.e9; doi: 10.1016/j.ccell.2023.09.011
28.
WuH-X, PanY-Q, HeY, et al.Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-Expressing esophageal squamous cell carcinoma: A post hoc analysis of JUPITER-06 and meta-analysis. J Clin Oncol, 2023; 41(9):1735–1746; doi: 10.1200/JCO.22.01490
29.
ZhangX, YangY, ZhaoH, et al.Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma. J Pathol Clin Res, 2024; 10(4):e12390; doi: 10.1002/2056-4538.12390
30.
WangL, ZhangX, MaX, et al.Elevated Sera IL-6 and NK-T cells associated with increased pathological complete response in HER2-positive breast cancer with carboplatin-based neoadjuvant therapy. Altern Ther Health Med, 2023; 29(3):246–253.
31.
KaralisJD, JuMR, YoonLY, et al.Serum interleukin 6 level is associated with overall survival and treatment response in gastric and gastroesophageal junction cancer. Ann Surg, 2023; 278(6):918–924; doi: 10.1097/SLA.0000000000005997
32.
Moreno AyalaMA, CampbellTF, ZhangC, et al.CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity. Immunity, 2023; 56(7):1613–1630.e5; doi: 10.1016/j.immuni.2023.06.003
33.
WangB, WangX, WangT, et al.Targeting PD-1 and CD85j can restore intratumoral CD4+ GzmB+ T-cell functions to combat MHC-II-expressing tumors. J Immunother Cancer, 2025; 13(4):e010890; doi: 10.1136/jitc-2024-010890
34.
LiJ, ShiD, LiS, et al.KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC. Cell Death Dis, 2024; 15(2):175; doi: 10.1038/s41419-024-06563-3
35.
SongM, QianC, ZhangT, et al.Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade. J Ethnopharmacol, 2023; 316:116735; doi: 10.1016/j.jep.2023.116735
36.
FortunatoM, AmodioG, GregoriS. IL-10-Engineered dendritic cells modulate allogeneic CD8+ T cell responses. Int J Mol Sci, 2023; 24(11):9128; doi: 10.3390/ijms24119128
37.
SchmidtME, VargaSM. Cytokines and CD8 T cell immunity during respiratory syncytial virus infection. Cytokine, 2020; 133:154481; doi: 10.1016/j.cyto.2018.07.012
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
